Nanomedicine (London, England)最新文献_第5页

(Re)evolution in nanoparticles-loaded microneedle delivery systems: are we getting closer to a clinical translation? （再）纳米粒子负载微针输送系统的进化：我们离临床转化更近了吗？

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-21 DOI: 10.1080/17435889.2025.2492538

Antonio José Guillot, Ana Melero

{"title":"(Re)evolution in nanoparticles-loaded microneedle delivery systems: are we getting closer to a clinical translation?","authors":"Antonio José Guillot, Ana Melero","doi":"10.1080/17435889.2025.2492538","DOIUrl":"https://doi.org/10.1080/17435889.2025.2492538","url":null,"abstract":"The deposition of drug-loaded nanoparticles within the skin structure has been a challenge due to the inexorable skin barrier function. Unless specific nanoparticles like liposomes and lipid-based related vesicles, most nanoparticles cannot penetrate the epidermal layers by themselves. This is the reason why microneedle-based systems are nowadays the most straightforward systems in skin research. They can greatly bypass the stratum corneum and deposit the supramolecular cargo entities in the dermal layers, which can perform specific features such as drug-controlled release, specific targeting or stimuli-responsive behaviors. At this point, after more than 20 years of research using this nanoparticle-microneedle combination and all the positive results, the clinical experience is still so limited. Therefore, how is it possible that the everlasting promise of the clinical translation of these systems has not reached a real clinical practice? In this piece of work, based on authors' review, a series of limiting factors as the regulatory framework and guidelines are identified and discussed, while it is highlighted that revolutionary advances in the biomedical field such as 3D-printing technology and microfluidics will contribute to accelerate the clinical translation of nanoparticle-microneedle-based devices and make possible their use and entrance to the biomedical market.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1195-1207"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging nanoparticle-based x-ray imaging contrast agents for breast cancer screening. 新兴的基于纳米颗粒的乳腺癌筛查x射线成像造影剂。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-22 DOI: 10.1080/17435889.2025.2496129

Katherine J Mossburg, Diego Barragan, Nathaniel H O, Andrea C Kian, Andrew D A Maidment, David P Cormode

{"title":"Emerging nanoparticle-based x-ray imaging contrast agents for breast cancer screening.","authors":"Katherine J Mossburg, Diego Barragan, Nathaniel H O, Andrea C Kian, Andrew D A Maidment, David P Cormode","doi":"10.1080/17435889.2025.2496129","DOIUrl":"https://doi.org/10.1080/17435889.2025.2496129","url":null,"abstract":"Breast cancer is one of the most common types of cancer, however, preventive screening has contributed to a significant reduction in mortality over the past four decades. The first-line screening methods for breast cancer, such as mammography and tomosynthesis, are x-ray-based modalities. Unfortunately, their cancer detection rates are low in patients with dense breasts. These, and other high-risk women, are now encouraged to receive supplemental screening. The supplemental imaging methods are diverse, including ultrasound, MRI, nuclear imaging, and X-ray-based modalities such as breast CT and contrast-enhanced mammography/tomosynthesis. Due to their low cost and wide availability, x-ray-based modalities see significant clinical use worldwide. These techniques benefit from the use of contrast agents, which are currently iodinated small molecules designed for other purposes. Consequently, developing new contrast agents that are specifically for breast cancer screening is of interest. This review describes these modalities and the nanoparticle-based contrast agents being researched for their enhanced performance. The relevant parameters for nanoparticle-based contrast agent design are evaluated, including contrast generation and potential biointeractions. Iodinated agents are discussed for comparison. Nanoparticles covered include silver sulfide, silver telluride, gold, and bismuth sulfide-based agents, among others. Finally, perspectives on future developments in this field are offered.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1149-1166"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The distinct properties of high-density lipoprotein nanoparticles as ocular drug delivery vehicles. 高密度脂蛋白纳米颗粒作为眼部给药载体的独特特性。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-02-21 DOI: 10.1080/17435889.2025.2469489

Tatsuya Murakami, Haruka Kurita

引用次数: 0

MXene and prostate cancer: is there promising news? MXene和前列腺癌：有好消息吗？

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-16 DOI: 10.1080/17435889.2025.2487412

Mohammad Reza Fattahi, Mostafa Baghlani, Scott E Eggener, Mansoureh Dehghani, Mohammad-Mehdi Khani, Abdolmohammad Kajbafzadeh

{"title":"MXene and prostate cancer: is there promising news?","authors":"Mohammad Reza Fattahi, Mostafa Baghlani, Scott E Eggener, Mansoureh Dehghani, Mohammad-Mehdi Khani, Abdolmohammad Kajbafzadeh","doi":"10.1080/17435889.2025.2487412","DOIUrl":"https://doi.org/10.1080/17435889.2025.2487412","url":null,"abstract":"Prostate cancer is the most prevalent cancer among men worldwide, and there have been many advances in its diagnosis and treatment. However, critical obstacles remain, including overdiagnosis, high rates of negative biopsies, management of side effects, and the timely detection of relapse. Despite these improvements, surgery and radiotherapy are still associated with a significant risk of short- or long-term side effects. MXenes are a novel class of two-dimensional nanomaterials manufactured through electrochemical procedures that accept a wide-termination of hydrophilic molecules as surface modifications. The importance of MXene has increased owing to many aspects, such as its high-gain synthesis potential, chemical flexibility, and high biocompatibility. Hence, MXene is a convenient nanomaterial that can be modified and synthesized in different models, suggesting its ability to improve screening, diagnosis, and theranostic applications, such as thermal therapy. These features have been used to detect potential urothelial tumor markers as well as the direction and accumulation of cancer medications in the target tissue.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 9","pages":"1001-1014"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in cancer nanovaccines: a focus on colorectal cancer. 癌症纳米疫苗的进展：以结直肠癌为重点。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-05 DOI: 10.1080/17435889.2025.2486930

Yalda Ghazizadeh, Hossein Salehi Shadkami, Fatemeh Madani, Sedigheh Niknam, Mahdi Adabi

引用次数: 0

Statement of Retraction: Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. 撤回声明：四碘甲乙酸偶联PLGA纳米颗粒：一种治疗耐药乳腺癌的纳米医学方法。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-03 DOI: 10.1080/17435889.2025.2488633

引用次数: 0

The emerging role of graphene in spinal cord regeneration. 石墨烯在脊髓再生中的新作用。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-03-07 DOI: 10.1080/17435889.2025.2475732

Paula A A P Marques

引用次数: 0

Nanomaterials for bacterial enrichment and detection in healthcare. 纳米材料在医疗保健中的细菌富集和检测。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-09 DOI: 10.1080/17435889.2025.2488724

Marwa Elhariry, Alina Oknianska, Jorge Garcia-Lara, Robert Shorten, Boris Oberheitmann, Tapas Sen

{"title":"Nanomaterials for bacterial enrichment and detection in healthcare.","authors":"Marwa Elhariry, Alina Oknianska, Jorge Garcia-Lara, Robert Shorten, Boris Oberheitmann, Tapas Sen","doi":"10.1080/17435889.2025.2488724","DOIUrl":"10.1080/17435889.2025.2488724","url":null,"abstract":"Bacterial infections in the blood (sepsis) have been recognized as a leading cause of mortality in the clinical field due to limitations in the detection of bacteria at low concentration and their resistance to antibiotics by excessive misuse. Some of the common symptoms are fever, chills, rapid heartbeat, difficulty breathing, confusion, and changes in mental status with occasionally pale, clammy, and mottled skin. Early diagnosis and identification are the keys to a successful treatment for sepsis patients. Researchers have developed nanoparticles to enrich bacterial populations followed by detection and applied them to conventional methods such as phenotypic and molecular diagnostics to enhance different detectors' responses toward pathogens. This short review systematically overviews steps that are followed in clinical labs for bacterial detection, identification, and their drawbacks. In this context, we discuss the role that nanoparticles can play in overcoming the limits of traditional microbiology methods in terms of turnaround times (TATs) and accuracy. We believe that this short review will provide up-to-date information about the applications of nanoparticles in the enrichment, separation, and identification of bacterial infection in the clinical field and, therefore, a way of rapid treatment.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"985-1000"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Specific quantification of intact lipid nanocapsules in rats using FRET: biodistribution and PBPK model development. 利用FRET对大鼠完整脂质纳米胶囊的特异性定量：生物分布和PBPK模型的建立。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-24 DOI: 10.1080/17435889.2025.2492537

Rana Elfatairi, Jessica Ou, Vincent Lebreton, Mariam Mahdjoub, Norraseth Kaeokhamloed, Jérôme Bejaud, Grégory Hilairet, Florence Gattacceca, Emilie Roger, Samuel Legeay

{"title":"Specific quantification of intact lipid nanocapsules in rats using FRET: biodistribution and PBPK model development.","authors":"Rana Elfatairi, Jessica Ou, Vincent Lebreton, Mariam Mahdjoub, Norraseth Kaeokhamloed, Jérôme Bejaud, Grégory Hilairet, Florence Gattacceca, Emilie Roger, Samuel Legeay","doi":"10.1080/17435889.2025.2492537","DOIUrl":"https://doi.org/10.1080/17435889.2025.2492537","url":null,"abstract":"Aims: One major challenge is to quantify intact nanoparticles specifically to understand the pharmacokinetics (PK) of nanomedicines. Lipid nanocapsules (LNC) carrying Förster resonance energy transfer (FRET) trackers have been previously developed, and a quantification method has been applied in blood samples.Materials & method: A quantification method in liver, spleen, and lungs was developed, and the biodistribution of intact FRET-LNC of 50 nm (FRET-LNC-50) in rats after intravenous injection was performed.Results: FRET-LNC-50 were extracted from organs using a newly developed extraction method, allowing their integrity preservation and quantification. This method allowed the assessment of the biodistribution study of intact LNC. A non-compartmental PK analysis was performed to calculate PK parameters. The most exposed organ was the liver, with a longer half-life than blood and other organs. The availability of specific biodistribution data allowed the development of the first physiologically based PK (PBPK) model, which represents an ideal platform to further aggregate biodistribution data from various nanoparticle types and to bring insight into PK mechanisms and structure-properties relationships of nanoparticles.Conclusion: This study presents the first biodistribution analysis of intact LNC using a validated quantification method, enabling the development of a PBPK model that improves the understanding of nanoparticle PK mechanisms.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 10","pages":"1101-1112"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer. PEP503 （NBTXR3，放射线增强剂）与直肠癌患者放化疗的Ib/II期试验结果。

Nanomedicine (London, England) Pub Date : 2025-05-01 Epub Date: 2025-04-21 DOI: 10.1080/17435889.2025.2487411

Ching-Wen Huang, Huang-Ming Hu, Wen-Hung Hsu, Chiao-Yun Chen, Ming-Yii Huang, Chou-Pin Chen, Po-Li Wei, Bor-Nian Shen, Tsung-Kun Chang, Jaw-Yuan Wang

{"title":"Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer.","authors":"Ching-Wen Huang, Huang-Ming Hu, Wen-Hung Hsu, Chiao-Yun Chen, Ming-Yii Huang, Chou-Pin Chen, Po-Li Wei, Bor-Nian Shen, Tsung-Kun Chang, Jaw-Yuan Wang","doi":"10.1080/17435889.2025.2487411","DOIUrl":"https://doi.org/10.1080/17435889.2025.2487411","url":null,"abstract":"Aim: To evaluate the efficacy, recommended phase II dose (RP2D), dose-limiting toxicity (DLT), and safety profiles of PEP503 (NBTXR3) in combination with concurrent chemoradiotherapy (CCRT) in patients with locally advanced or unresectable rectal adenocarcinoma.Methods: A single administration of intratumor injection of PEP503 (NBTXR3) (multiple punctures) was applied, followed by radiotherapy in combination with capecitabine or 5-fluorouacil (5-FU). Surgery was performed 8 to 12 weeks after completion of CCRT.Results: Thirty-two patients were enrolled (one dropped out before CCRT), comprising 20 in phase Ib and 12 in phase II. The disease control rate was 100% (n = 31). One (3.2%) and 19 (61.3%) patients achieved clinical complete response and partial response, respectively. Twenty-five patients underwent surgery, of whom 24 (96%) had R0 resection and 5 (20%) had pathological complete response. Most of the adverse events were grade 1/2 events.Conclusion: Intratumor injection of PEP503 (NBTXR3) in patients with locally advanced or unresectable rectal adenocarcinoma is safe and effective. Addition of PEP503 (NBTXR3) to fluoropyrimidine-based neoadjuvant CCRT does not engender increased toxicity. The strong safety profile and encouraging efficacy of PEP503 (NBTXR3) in combination with neoadjuvant CCRT in locally advanced or unresectable rectal cancer warrant further examination in clinical studies.Clinical trial registration: This study was registered on ClinicalTrials.gov Identifier: NCT02465593.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 9","pages":"929-941"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0